[go: up one dir, main page]

MX2015008661A - Proceso para la obtencion de un derivado de fluorlactona. - Google Patents

Proceso para la obtencion de un derivado de fluorlactona.

Info

Publication number
MX2015008661A
MX2015008661A MX2015008661A MX2015008661A MX2015008661A MX 2015008661 A MX2015008661 A MX 2015008661A MX 2015008661 A MX2015008661 A MX 2015008661A MX 2015008661 A MX2015008661 A MX 2015008661A MX 2015008661 A MX2015008661 A MX 2015008661A
Authority
MX
Mexico
Prior art keywords
derivative
preparation
formula
fluorolacton
acylated
Prior art date
Application number
MX2015008661A
Other languages
English (en)
Inventor
Guoliang Zhu
Rongmin Chen
Yuanqiang Li
Jianqiang Zhao
Jianbing Zheng
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015008661A publication Critical patent/MX2015008661A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describe un nuevo proceso para la obtención de un derivado de fluorlactona de la fórmula: (ver Fórmula) y de su derivado acilado de la fórmula: (ver Fórmula) en la que R1 significa un grupo protector de hidroxi. Las fluorlactonas aciladas de la fórmula y, en especial el derivado benzoílo, en el que R1 = bencilo, son compuestos previos de síntesis importantes de compuestos profármacos, que tienen el potencial de ser potentes inhibidores de la polimerasa NS5B del virus de la hepatitis C (HCV).
MX2015008661A 2013-01-14 2014-01-13 Proceso para la obtencion de un derivado de fluorlactona. MX2015008661A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013070413 2013-01-14
PCT/EP2014/050439 WO2014108525A1 (en) 2013-01-14 2014-01-13 Process for the preparation of a fluorolacton derivative

Publications (1)

Publication Number Publication Date
MX2015008661A true MX2015008661A (es) 2015-10-05

Family

ID=49989697

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008661A MX2015008661A (es) 2013-01-14 2014-01-13 Proceso para la obtencion de un derivado de fluorlactona.

Country Status (14)

Country Link
US (2) US9624183B2 (es)
EP (1) EP2943475B1 (es)
JP (1) JP6317367B2 (es)
KR (2) KR20200138424A (es)
AR (1) AR094466A1 (es)
BR (1) BR112015016647A2 (es)
CA (1) CA2896253C (es)
ES (1) ES2655851T3 (es)
IL (1) IL239697A (es)
MX (1) MX2015008661A (es)
PT (1) PT2943475T (es)
RU (1) RU2656600C2 (es)
SG (1) SG11201505455VA (es)
WO (1) WO2014108525A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2734052A1 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
AR094466A1 (es) 2013-01-14 2015-08-05 Hoffmann La Roche Proceso para la obtención de un derivado de fluorlactona
CN105111169A (zh) * 2015-07-08 2015-12-02 重庆沃肯精细化工有限公司 一种索菲布韦关键中间体的简便制备方法
CN109843860A (zh) * 2016-08-16 2019-06-04 上海泓博智源医药股份有限公司 制备内酯衍生物及其中间体的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336247B (zh) 2005-12-09 2013-01-23 豪夫迈·罗氏有限公司 抗病毒核苷
KR101118413B1 (ko) * 2006-12-18 2012-03-07 에프. 호프만-라 로슈 아게 3,5-다이-ｏ-아실-2-플루오로-2-ｃ-메틸-ｄ-리보노-감마-락톤의 제조 방법
WO2008090046A1 (en) * 2007-01-23 2008-07-31 F. Hoffmann-La Roche Ag Alternate process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-ribono-gamma-lactone
AR094466A1 (es) 2013-01-14 2015-08-05 Hoffmann La Roche Proceso para la obtención de un derivado de fluorlactona

Also Published As

Publication number Publication date
US20150315165A1 (en) 2015-11-05
CA2896253C (en) 2021-01-12
ES2655851T3 (es) 2018-02-21
HK1215020A1 (zh) 2016-08-12
HK1219094A1 (en) 2017-03-24
EP2943475A1 (en) 2015-11-18
US9845299B2 (en) 2017-12-19
JP6317367B2 (ja) 2018-04-25
WO2014108525A1 (en) 2014-07-17
IL239697A (en) 2017-12-31
IL239697A0 (en) 2015-08-31
CA2896253A1 (en) 2014-07-17
AR094466A1 (es) 2015-08-05
KR20150104205A (ko) 2015-09-14
JP2016508154A (ja) 2016-03-17
RU2015130337A (ru) 2017-02-20
BR112015016647A2 (pt) 2017-07-11
RU2656600C2 (ru) 2018-06-06
KR102187280B1 (ko) 2020-12-07
KR20200138424A (ko) 2020-12-09
EP2943475B1 (en) 2017-10-25
PT2943475T (pt) 2018-01-17
SG11201505455VA (en) 2015-08-28
US9624183B2 (en) 2017-04-18
US20170183317A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
PH12020550552A1 (en) Inhibitors of hepatitis c virus
MX362060B (es) Compuestos antivirales inhibidores del virus de hepatitis c (vhc) ns5b.
PH12017500408A1 (en) Heteroaryl compunds as btk inhibitors and uses thereof
IN2014MN02658A (es)
IN2014MN02657A (es)
IN2014MN02652A (es)
IN2014CN04530A (es)
SG194749A1 (en) Hepatitis c virus inhibitors
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
MX377552B (es) Proceso para preparar un compuesto antiviral de formula i.
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
CO6561783A2 (es) Inhibidores del virus flaviviridae
MY187617A (en) Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof
WO2013074386A3 (en) Hcv ns3 protease inhibitors
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
NZ720745A (en) Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide
PH12016500394A1 (en) Polymorphic form of pyrrole derivative and intermediate thereof
MX2013014002A (es) Inhibidores del virus de la hepatitis c.
PH12015500814A1 (en) Hepatitis c virus inhibitors
NZ631182A (en) Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds
MX2015008661A (es) Proceso para la obtencion de un derivado de fluorlactona.
MX360161B (es) Proceso para preparar compuestos antiviricos.
NZ726343A (en) Antiviral compounds
MY176613A (en) Industrial process for the synthesis of ulipristal acetate and its 4'-acetyl analogue